Cartesian Therapeutics (RNAC) Common Equity (2016 - 2025)
Historic Common Equity for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$35.8 million.
- Cartesian Therapeutics' Common Equity fell 486648.94% to -$35.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.8 million, marking a year-over-year decrease of 486648.94%. This contributed to the annual value of -$6.8 million for FY2024, which is 9845.47% up from last year.
- Per Cartesian Therapeutics' latest filing, its Common Equity stood at -$35.8 million for Q3 2025, which was down 486648.94% from -$2.5 million recorded in Q2 2025.
- Cartesian Therapeutics' Common Equity's 5-year high stood at $93.8 million during Q4 2022, with a 5-year trough of -$440.2 million in Q4 2023.
- Its 5-year average for Common Equity is -$11.6 million, with a median of -$2.5 million in 2025.
- Per our database at Business Quant, Cartesian Therapeutics' Common Equity skyrocketed by 222235.91% in 2022 and then plummeted by 486648.94% in 2025.
- Over the past 5 years, Cartesian Therapeutics' Common Equity (Quarter) stood at $22.5 million in 2021, then skyrocketed by 316.62% to $93.8 million in 2022, then plummeted by 569.14% to -$440.2 million in 2023, then soared by 98.45% to -$6.8 million in 2024, then plummeted by 426.96% to -$35.8 million in 2025.
- Its last three reported values are -$35.8 million in Q3 2025, -$2.5 million for Q2 2025, and -$21.8 million during Q1 2025.